strive earlier for
In PSMA+ mCRPC,
A chance to live longer without progression.1,2 That's a Victory.
The first and only PSMA-targeted radioligand therapy to significantly delay progression after only 1 ARPI.
For patients without prior chemotherapy*
FDA approved
Median rPFS (primary end point) in the PSMAfore trial with PLUVICTO vs change in ARPI:
•Primary analysis: 9.3 months vs 5.6 months (HR=0.41 [95% CI, 0.29-0.56]; P<0.0001)1
•Updated exploratory analysis: 11.6 months vs 5.6 months (HR=0.49 [95% CI, 0.39-0.61])2,†
Not an actual patient.
